A Randomized, Double Blind Placebo Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYGK1, a Novel Glucokinase Activator, Following Oral Administration in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs ZY GK1 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Cadila Healthcare
- 10 Jun 2017 Biomarkers information updated
- 23 Nov 2015 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
- 29 Jan 2014 Planned End Date changed from 1 Sep 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov record.